- Corporate Officers - P
- Proehl Gerald T
Insider Trading History of Proehl Gerald T
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Proehl Gerald T since 2005.
This trader's CIK number is 1279191.
At the time of last reporting, Proehl Gerald T was the Officer of Tenax Therapeutics, Inc.. (stock ticker symbol TENX).
Also see all insider trading activities at Tenax Therapeutics, Inc..
Note that in the past
PROEHL GERALD T also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Sophiris Bio Inc. (SPHS) by Proehl Gerald T
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2014 | SPHS | 10,000 | $31,600 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Auspex Pharmaceuticals, Inc. (ASPX) by Proehl Gerald T
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2014 | ASPX | 1,466 | $31,885 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Qualigen Therapeutics, Inc. (RTTR) by Proehl Gerald T
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2015 | RTTR | 50,000 | $250,000 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Tenax Therapeutics, Inc. (TENX) by Proehl Gerald T
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2024 | TENX | 1,666 | $0 | 0 | $0 | 0 | $0 |
2016 | TENX | 29,882 | $49,968 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Santarus Inc (SNTS) by Proehl Gerald T
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2013 | SNTS | 0 | $0 | 473,092 | $10,096,263 | 373,092 | $623,831 |
2011 | SNTS | 0 | $0 | 0 | $0 | 114,285 | $99,999 |
2010 | SNTS | 0 | $0 | 0 | $0 | 85,714 | $89,999 |
2009 | SNTS | 40,000 | $49,000 | 0 | $0 | 38,571 | $40,499 |
2008 | SNTS | 0 | $0 | 0 | $0 | 70,000 | $49,000 |
2007 | SNTS | 25,000 | $68,775 | 10,000 | $69,860 | 0 | $0 |
2006 | SNTS | 0 | $0 | 87,500 | $625,724 | 0 | $0 |
2005 | SNTS | 10,000 | $31,100 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Dermata Therapeutics, Inc. (DRMA) by Proehl Gerald T
| | Insider Buying | Insider Sales | Option Exercises |
---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
---|
2021 | DRMA | 172,857 | $97,630 | 0 | $0 | 0 | $0 |
Insider trading activities at 6 companies by Proehl Gerald T:
1. Sophiris Bio Inc. (SPHS)
2. Auspex Pharmaceuticals, Inc. (ASPX)
3. Qualigen Therapeutics, Inc. (RTTR)
4. Tenax Therapeutics, Inc. (TENX)
5. Santarus Inc (SNTS)
6. Dermata Therapeutics, Inc. (DRMA)
Table 1. Insider trading of Sophiris Bio Inc. (SPHS) by Proehl Gerald T
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2014-09-19 | SPHS | Buy | 10,000 | 3.16 | 31,600 |
Table 2. Insider trading of Auspex Pharmaceuticals, Inc. (ASPX) by Proehl Gerald T
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2014-09-19 | ASPX | Buy | 1,466 | 21.75 | 31,885 |
Table 3. Insider trading of Qualigen Therapeutics, Inc. (RTTR) by Proehl Gerald T
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2015-06-24 | RTTR | Buy | 50,000 | 5.00 | 250,000 |
Table 4. Insider trading of Tenax Therapeutics, Inc. (TENX) by Proehl Gerald T
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2024-08-08 | TENX | Buy | 1,666 | .00 | 0 |
2016-11-23 | TENX | Buy | 14,449 | 1.76 | 25,430 |
2016-11-22 | TENX | Buy | 15,433 | 1.59 | 24,538 |
Table 5. Insider trading of Santarus Inc (SNTS) by Proehl Gerald T
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2013-12-16 | SNTS | Option Ex | 56,643 | 3.50 | 198,250 |
2013-12-16 | SNTS | Sale | 56,643 | 31.95 | 1,809,460 |
2013-11-15 | SNTS | Option Ex | 56,644 | 3.50 | 198,254 |
2013-11-15 | SNTS | Sale | 56,644 | 32.02 | 1,813,684 |
2013-10-15 | SNTS | Sale | 50,000 | 22.32 | 1,116,100 |
2013-09-16 | SNTS | Sale | 50,000 | 22.19 | 1,109,550 |
2013-05-06 | SNTS | Option Ex | 86,603 | .88 | 75,777 |
2013-05-06 | SNTS | Sale | 86,603 | 18.73 | 1,622,507 |
2013-04-04 | SNTS | Sale | 86,601 | 16.75 | 1,450,133 |
2013-04-04 | SNTS | Option Ex | 86,601 | .88 | 75,775 |
2013-03-04 | SNTS | Option Ex | 86,601 | .88 | 75,775 |
2013-03-04 | SNTS | Sale | 86,601 | 13.57 | 1,174,829 |
2011-12-08 | SNTS | Option Ex | 59,285 | .88 | 51,874 |
2011-09-30 | SNTS | Option Ex | 55,000 | .88 | 48,125 |
2010-11-09 | SNTS | Option Ex | 85,714 | 1.05 | 89,999 |
2009-11-03 | SNTS | Option Ex | 38,571 | 1.05 | 40,499 |
2009-03-16 | SNTS | Buy | 40,000 | 1.23 | 49,000 |
2008-10-23 | SNTS | Option Ex | 70,000 | .70 | 49,000 |
2007-12-11 | SNTS | Buy | 25,000 | 2.75 | 68,775 |
2007-01-24 | SNTS | Sale | 10,000 | 6.99 | 69,860 |
2006-10-16 | SNTS | Sale | 12,500 | 8.36 | 104,450 |
2006-09-15 | SNTS | Sale | 12,500 | 8.24 | 103,025 |
2006-08-15 | SNTS | Sale | 12,500 | 6.28 | 78,500 |
2006-07-20 | SNTS | Sale | 7,448 | 6.00 | 44,688 |
2006-07-17 | SNTS | Sale | 5,052 | 6.00 | 30,337 |
2006-05-15 | SNTS | Sale | 12,500 | 6.99 | 87,312 |
2006-04-17 | SNTS | Sale | 12,500 | 7.92 | 99,037 |
2006-03-15 | SNTS | Sale | 12,500 | 6.27 | 78,375 |
2005-05-31 | SNTS | Buy | 10,000 | 3.11 | 31,100 |
Table 6. Insider trading of Dermata Therapeutics, Inc. (DRMA) by Proehl Gerald T
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|
2021-11-23 | DRMA | Buy | 20,000 | 2.40 | 48,000 |
2021-08-16 | DRMA | Buy | 10,000 | 4.96 | 49,630 |
2021-08-17 | DRMA | Buy | 142,857 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Proehl Gerald T
(Officer of Tenax Therapeutics, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.